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1. Introduction 
Dialysis patients are at high risk for aluminum overload, especially patients with 
hyperparathyroidism, who may occasionally take aluminum-containing phosphate binders. 
Dialysis patients with aluminum overload may have various symptoms, such as general 
bone or muscle pain, iron-resistant anemia, hypercalcemia, and neurologic abnormalities, 
which are sometimes difficult to differentiate from clinical manifestations of 
hyperparathyroidism. Because of the different therapeutic strategies between aluminum 
overload and hyperparathyroidism, an overview of aluminum overload in dialysis patients 
with hyperparathyroidism is presented in the following sections. 
2. Aluminum overload in dialysis patients 
Dialysis patients are at high risk for aluminum overload (Jaffe, J.A. et al., 2005) because of 
long-term use of aluminum-containing phosphate binders (Humpfner, A. et al., 1993; 
Salusky, I.B., 2006), poor renal excretion of aluminum, and contact with aluminum-
containing dialysate. Aluminum can be eliminated from dialysate by using reverse osmosis 
and deionization techniques. The dialysate concentration of aluminum is suggested to be 
maintained at <10 µg/L (Fernández-Martin, J.L. et al., 1998; National Kidney Foundation 
[NKF], 2003). Therefore, aluminum-containing phosphate binders had been documented as 
the predominant source of aluminum exposure in dialysis patients (Savory, J. et al., 1989; 
Slatopolsky, E., 1987). Because of multiple systemic aluminum-related complications, 
reducing the exposure of dialysis patients to aluminum by substituting calcium- and other 
non-aluminum-based phosphate binders is a well-known concept. However, some patients 
with refractory hyperphosphatemia or calcium-induced hypercalcemia still require 
aluminum therapy (NKF, 2003). While aluminum-based phosphate binders used as short-
term therapy are suggested by the Kidney Disease Outcomes Quality Initiative (K/DOQI) 
guidelines, these medications are prohibited in some countries (Koiwa, F., & Sato, Y., 2009). 
Non-calcium and non-aluminum phosphate binders (such as sevelamer hydrochloride and 
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lanthanum carbonate) are suggested as substitutes. However, these newly developed 
medications have not become popular in many countries because of their high cost (Koiwa, 
F. & Sato, Y., 2009). In addition, the source of aluminum may contribute to extra aluminum 
intake from other medications (Bohrer, D. et al., 2009). Therefore, aluminum overload is still 
a potential problem in the dialysis population. 
2.1 Frequency of aluminum overload 
The declining exposure of aluminum-containing dialysate and medications with commonly 
use of high flux dialyzers has resulted in a low incidence of abnormal aluminum levels in 
current dialysis patients (Cannata-Andía, J.B. & Fernández-Martín, J.L., 2002). In one 
retrospective study on more than 43,000 dialysis patients, 2.5% of the patients had elevated 
serum aluminum levels (>50 g/L) that significantly declined year by year (Jaffe, J.A. et al., 
2005). However, the prevalence of aluminum overload might be higher in countries that still 
commonly used aluminum-containing phosphate binders (Kan, W.C. et al., 2010).  
2.2 Clinical manifestations of aluminum overload 
Aluminum can accumulate in many human organs; this accumulation has been implicated in 
various diseases, including dialysis encephalopathy, aluminum-induced bone disease (such as 
osteomalacia), hypercalcemia, and iron-resistant microcytic anemia (NKF, 2003; Berlyne,  
G.M. et al., 1970, 1972; Sherrard, D.J., 1974; Alfrey, A.C. et al., 1976, 1987; Ward, M.K. et al., 
1978; Parkinson, I.S. et al., 1979; Drüeke T., 1980; Hewitt, C.D. et al., 1990). (Summary  
of Aluminum-related disorders: Features, Causes, and Considerations for therapy, 
http://www.kidney.org/professionals/kdoqi/guidelines_bone/images/table31l.jpg)  
2.2.1 Dialysis encephalopathy 
Dialysis encephalopathy is usually a slowly progressive disorder with symptoms appearing 
after a patient has undergone dialysis for 1 year or even longer. Increased aluminum is found 
in the brain tissue of affected patients (Alfrey, A.C. et al., 1976). It is characterized by 
myoclonic jerks, mental changes, speech disturbances, visual or auditory hallucinations, 
paranoid behaviors, and even seizures. These neurologic abnormalities maybe fluctuate and 
often worsen temporarily after hemodialysis. The typical electroencephalographic (EEG) 
findings differ from the generalized slow wave with other causes of metabolic encephalopathy 
(Hughes, J.R. & Schreeder, M.T., 1980). However, due to its insidious progression, diagnosing 
these neurological disorders depends on clinical observation and suspicion, the finding of 
elevated plasma aluminum levels, and associated EEG features. New cases of dialysis 
encephalopathy disappeared after the initiation of water purification in 1979, and no more 
new cases have been reported in the developed countries since then (NKF, 2003). 
2.2.2 Aluminum-induced bone disease 
Aluminum can affect normal bone formation via several mechanisms. First, it interferes with 
mineralization of the matrix by forming crystals to compete for the site of calcium 
deposition, and it inhibits the activity of osteoblasts, both of which impair bone-building 
(Jeffery, E.H. et al., 1996). Second, it binds in the parathyroid gland, which inhibits the 
normal secretion of parathyroid hormone (PTH) (Cannata, J.B. et al., 1988), and it impairs 
PTH synthesis at the transcriptional level (Díaz-Corte, C. et al., 2001). Because of abnormal 
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bone formation, osteomalacia is the most frequently seen aluminum-induced bone disease, 
but its prevalence is reported to have markedly decreased after reduced exposure to 
aluminum (NKF, 2003). Osteomalacia is characterized by a low rate of bone turnover, a 
decreased number of bone-forming and bone-resorbing cells, and an increased volume of 
unmineralized bone (Delmez, J.A. & Slatopolsky, E., 1992;  Slatopolsky, E., 1987). In 
addition, because of its potential to excessively suppress PTH, aluminum overload may 
cause adynamic bone disease in a minority of cases. 
2.2.3 Anemia 
Aluminum can also affect normal hemopoietic processes via several mechanisms. First, it 
impairs intestinal absorption, serum transport, and cellular uptake of iron, because 
aluminum and iron share a common absorption pathway and, in the serum, they are 
transported on the same carriers in humans (Kausz, A.T. et al., 1999). These carriers include 
large proteins (such as transferrin and albumin) and small molecules (such as citrate and 
phosphate). In several animal and human studies, a significant negative correlation was 
found between aluminum load and iron transferrin saturation (Cannata, J.B. et al., 1991), 
and additional reductions in the use of aluminum-containing medications led to significant 
increases in hemoglobin and reductions in the need for intravenous iron supplementation in 
hemodialysis patients (Cannata, J.B. et al., 1983a). Second, aluminum may induce resistance 
to the hematopoietic effects of recombinant human erythropoietin (rHuEPO) in both rats 
and dialysis patients (Drüeke, T.B., 1990; Losekann, A. et al., 1990). Therefore, dialysis 
patients with an obvious aluminum overload may need larger doses of rHuEPO to 
overcome this resistance, which significantly increases the cost of patient care. 
2.2.4 Hypercalcemia 
Aluminum-related bone disease may cause hypercalcemia (Norris, K.C. et al., 1985). In a rat 
study, aluminum changed the relationships between serum PTH, calcium, and phosphorus 
(Felsenfeld, A.J. et al., 1993). In a study of 25 patients on continuous ambulatory peritoneal 
dialysis (Cannata, J.B. et al., 1983b) who had accidentally been exposed to high level of 
aluminum in the dialysate for a month, serum calcium levels significantly increased from 
2.27 to 2.44 mmol/L, while serum PTH levels declined from 744 to 580 ng/L. In another 
study of hemodialysis patients (Cannata, J.B. et al., 1983c), a high serum aluminum level was 
strongly associated with hypercalcemia and low serum PTH level. Therefore, the suspicion 
of aluminum overload should be kept in mind in the patient who does not have obvious 
elevations in serum intact PTH (e.g., less than 500 pg/mL) or who is not taking vitamin D 
therapy (NKF, 2003). 
2.3 Screening and diagnosis for aluminum overload 
A histological examination of bone biopsy specimens is still considered the gold standard for 
diagnosing dialysis patients with an aluminum overload. Biopsies, however, are invasive and 
expensive. Therefore, several studies have reported their efforts to develop less invasive 
diagnostic methods of diagnosing aluminum overload (Milliner, D.S. et al., 1984). Serum 
aluminum measurements are of limited value due to its high tissue accumulation. However, 
aluminum overload is unlikely in dialysis patients with baseline serum aluminum 
concentrations (without desferrioxamine (DFO) “stimulation”) less than 20 µg/L (NKF, 2003). 
In one study, 50 dialysis patients undergoing bone biopsy seemed distinguishable, after a DFO 
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infusion test, from those with a positive bone aluminum stain by an increase in serum 
aluminum and a relatively high serum iPTH level (McCarthy, J.T. et al., 1990). In another 
prospective study of 445 dialysis patients to evaluate noninvasive tests that combined the 
results of intact parathyroid hormone (iPTH) and DFO tests (Pei, Y. et al., 1992), the test were 
useful for predicting aluminum-related bone disease in dialysis patients using aluminum-
based binders. However, they yielded a high incidence of false-negatives and low-sensitivity 
results after these patients had discontinued aluminum-based binders for more than 6 months. 
According to the present consensus, the DFO test affords a non-invasive method to identify 
patients with an increased body burden of aluminum (NKF, 2003) (Evaluation of aluminum-
related disorders: considerations for DFO test and subsequent DFO treatment, 
http://www.kidney.org/professionals/kdoqi/guidelines_bone/Images/Algorithm7L.jpg). 
2.4 Treatment 
In addition to dialysis modalities, the K/DOQI guideline (NKF, 2003) also recommends 
DFO to treat dialysis patients with an aluminum overload. However, DFO has side effects of 
its own (Cronin, R.E. & Henrich, W.L., 2006), such as itchy skin, nausea, myalgia, and 
neurotoxicity (McCauley, J. & Sorkin, M.I., 1989). Although most of these side effects are 
mild and reversible, some rare and severe or even life-threatening side effects are possible, 
especially anaphylactic shock and mucormycosis (Boelaert, J.R. et al., 1991, 1993). Because of 
the common side effects of DFO, doses of 20-40 mg/kg of body weight (Bene, C. et al., 1989; 
Cases, A. et al., 1988; Pengloan, J. et al., 1987) have been abandoned. The toxicity of DFO is 
dose-dependent; thus, many studies (Barata, J.D. et al., 1996; D'Haese, P.C. et al., 1995; 
Janssen, M.J. & van Boven, W.P., 1996) were designed to find the optimal dose for 
aluminum overload treatment. According to the K/DOQI clinical practice guideline (NKF, 
2003), the DFO standard dose is 5 mg/kg of body weight (DFO treatment, 
http://www.kidney.org/professionals/kdoqi/guidelines_bone/Images/Algorithm9L.jpg). 
Furthermore, several pharmacokinetic and small-scale, short-term studies (Canteros, A. et 
al., 1998; Jorge, C. et al., 1999) found that even doses lower than 5 mg/kg were as efficacious 
as the standard 5 mg/kg dose, but clinical trials verifying its efficacy at lower doses are 
lacking. Therefore, we compared the response to 2 months of treatment with the standard 
dose (5 mg/kg) versus a lower dose (2.5 mg/kg) of DFO in dialysis patients with aluminum 
overload. Both treatment groups showed similar therapeutic effects, there were relatively 
fewer side effects in the 2.5-mg/kg group (Kan, W.C. et al., 2010). 
3. Managing aluminum overload in dialysis patients with 
hyperparathyroidism 
In patients with hyperparathyroidism, calcium-based phosphate binders are always unsuitable 
because of the frequently associated symptoms of hypercalcemia. Therefore, aluminum-based 
binders were used, which created a high risk of aluminum overload. Because PTH can protect 
against aluminum deposition at the mineralization front, perhaps by increasing bone turnover 
(Slatopolsky, E., 1987), the symptoms of aluminum-related bone diseases may be “masked” in 
dialysis patients with hyperparathyroidism. However, this “protection” will disappear in 
patients who have undergone a parathyroidectomy (PTX), because lowered PTH levels will 
accelerate bone aluminum deposition (Slatopolsky, E., 1987). Therefore, it is generally 
suggested that aluminum bone disease be excluded before PTX. Similarly, medical treatment 
of hyperparathyroidism with active Vitamin D3 (calcitriol) also may accelerate aluminum bone 
disease. In addition, the risk of aluminum bone disease is greater in diabetics (Andress, D.L. et 
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al., 1987; Pei, Y. et al., 1993), which may be related to a lower bone turnover rate, which has 
been reported in type 1 diabetics before the onset of clinical renal disease (Andress, D.L. et al., 
1987; Vincenti, F. et al., 1984). Therefore, because of the sometimes similar clinical 
manifestations of hyperparathyroidism and aluminum overload, physicians treating dialysis 
patients with hyperparathyroidism should consider the possibility of concurrent aluminum 
problems, especially in high-risk diabetic patients. 
The side effects of DFO are dose-dependent and potentially life-threatening. Although the 
standard dose for aluminum overload is 5 mg/kg/week for a total of 8 weeks, there are still 
reports of fatal mucormycosis on such a regimen (Petrikkos, G. & Drogari-Apiranthitou, M., 
2011). A lower dose of DFO, if it offers good efficacy with fewer side effects, may be 
promising for managing such complicated patients (Kan, W.C. et al., 2010). 
4. Conclusion 
Although the prevalence of aluminum overload in dialysis patients is decreasing, it is still 
an insidious problem worldwide, especially in these dialysis patients still often exposed to 
aluminum-containing medications. In these patients with hyperparathyroidism, calcium- 
and aluminum-based binders are not suitable for long-term use (particularly for patients on 
concurrent vitamin D therapy). Therefore, in these particular patients, especially those with 
a history of aluminum-containing medications or water exposure, possible concurrent 
aluminum overload should be kept in mind before medical or surgical intervention. 
Otherwise, aluminum-related bone disease will be aggravated after treatments. Therefore, 
several non-calcium, non-aluminum phosphate binders (such as sevelamer hydrochloride 
and lanthanum carbonate) are suggested despite the high cost and consequent unpopularity 
of these newly developed medications. 
5. Acknowledgment 
Sincerely thankful to Miss Hui-Li Hsiao, the Matron of the Dialysis Center in Chi-Mei 
Medical Center, and all the staff nurses, whose full support and encouragement enabled us 
to complete the related studies. 
6. References 
Alfrey, A.C., LeGendre, G.R., Kaehny, W.D. (1976). The dialysis encephalopathy syndrome. 
Possible aluminum intoxication. N Engl J Med., Vol. 294, pp. 184–188, ISSN 1533-4406 
Alfrey A.C. (1987). Aluminum metabolism and toxicity in uremia. J UOEH., Vol. 9, Suppl, 
pp. 123–132, ISSN 0387-821X 
Andress, D.L., Kopp, J.B., Maloney, N.A., Coburn, J.W., Sherrard, D.J. (1987). Early 
deposition of aluminum in bone in diabetic patients on hemodialysis. N Engl J 
Med., Vol. 316, No. 6, pp. 292-296, ISSN 1533-4406 
Barata, J.D., D'Haese, P.C., Pires, C., Lamberts, L.V., Simões, J., De Broe, M.E. (1996). Low-
dose (5 mg/kg) desferrioxamine treatment in acutely aluminium-intoxicated 
haemodialysis patients using two drug administration schedules. Nephrol Dial 
Transplant., Vol. 11, No. 1, pp. 125-132, ISSN 1460-2385 
Bene, C., Manzler, A., Bene, D., Kranias, G. (1989). Irreversible ocular toxicity from single 
"challenge" dose of deferoxamine. Clin Nephrol., Vol. 31, No. 1, pp. 45-48, ISSN 
0301-0430 
www.intechopen.com
 
Hyperparathyroidism 
 
64
Berlyne, G.M., Pest, D., Ben-Ari, J., Weinberger, J., Stern, M., Gilmore, G.R., Levine, R. 
(1970). Hyperaluminaemia from aluminum resins in renal failure. Lancet, Vol. 296, 
No. 7671, pp. 494–496, ISSN 1474-547X 
Berlyne, G.M., Ben-Ari, J., Knopf, E., Yagil, R., Weinberger, G., Danovitch, G.M. (1972). 
Aluminium toxicity in rats. Lancet, Vol. 299, No. 7750, pp. 564–568, ISSN 1474-547X 
Boelaert, J.R., Fenves, A.Z., Coburn, J.W. (1991). Deferoxamine therapy and mucormycosis 
in dialysis patients: Report of an international registry. Am J Kidney Dis., Vol. 18, 
pp. 660-667, ISSN 1523-6838 
Boelaert, J.R., de Locht, M., Van Cutsem, J., Kerrels, V., Cantinieaux, B., Verdonck, A., Van 
Landuyt, H.W., Schneider, YJ. (1993). Mucormycosis during deferoxamine therapy 
is a siderophore-mediated infection. In vitro and in vivo animal studies. J Clin 
Invest., Vol. 91, No. 5, pp. 1979-1986 
Bohrer, D., Bertagnolli, D.C., de Oliveira, S.M., do Nascimento, P.C., de Carvalho, L.M., 
Garcia, S.C., Arantes, L.C., Barros, E.J. (2009). Role of medication in the level of 
aluminium in the blood of chronic renal patients. Nephrol Dial Transplant., Vol. 24, 
pp. 1277-1281, ISSN 1460-2385 
Cannata, J.B., Ruiz Alegria, P., Cuesta, M.V., Herrera, J., Peral, V. (1983). Influence of 
aluminium hydroxide intake on haemoglobin concentrations and blood transfusion 
requirements in haemodialysis patients. Proc Eur Dial Transplant Assoc., Vol. 20, pp. 
719–724, ISSN 0308-9401 
Cannata, J.B., Junor, B.J., Briggs, J.D., Fell, G.S., Beastall, G. Effect of acute aluminium 
overload on calcium and parathyroid-hormone metabolism. (1983). Lancet, Vol. 321, 
No. 8323, pp. 501–503, ISSN 1474-547X 
Cannata, J.B., Briggs, J.D., Junor, B.J., Beastall, G., Fell, G.S. (1983). The influence of 
aluminium on parathyroid hormone levels in haemodialysis patients. Proc Eur Dial 
Transplant Assoc., Vol. 19, pp. 244–247, ISSN 0308-9401 
Cannata, J.B., Diaz Lopez, J.B., Fernandez Menendez, M.J., Virgos, M.J. (1988). The 
parathyroid gland and aluminum overload: an overview. Contrib Nephrol., Vol. 64, 
pp. 113–119, ISSN 0302-5144 
Cannata, J.B., Fernández-Soto, I., Fernández-Menendez, M.J., Fernández-Martín, J.L., McGregor, 
S.J., Brock, J.H., Halls, D. (1991). Role of iron metabolism in absorption and cellular 
uptake of aluminum. Kidney Int., Vol. 39, No. 4, pp. 799–803, ISSN 1523-1755 
Cannata, J.B., and Fernández-Martín, J.L. (2002). The clinical impact of aluminium overload 
in renal failure. Nephrol Dial Transplant., Vol. 17, Suppl 2, pp. 9-12. 
Canteros, A., Díaz-Corte, C., Fernández-Martín, J.L., Gago, E., Fernández-Merayo, C., Cannata, 
J. (1998). Ultrafiltrable aluminium after very low doses of desferrioxamine. Nephrol 
Dial Transplant., Vol. 13, No. 6, pp. 1538-1542, ISSN 1460-2385 
Cases, A., Kelly, J., Sabater, J., Campistol, J.M., Torras, A., Montoliu, J., López, I., Revert, L. (1988). 
Acute visual and auditory neurotoxicity in patients with end-stage renal disease 
receiving desferrioxamine. Clin Nephrol., Vol. 29, No. 4, pp. 176-178, ISSN 0301-0430 
Cronin, R.E., and Henrich, W.L. (2006). Aluminum toxicity in end-stage renal disease. In: 
UpToDate, Rose, BD (Ed), UpToDate, Waltham, MA, ISSN 0301-5718 
Delmez, J.A., and Slatopolsky, E. (1992). Hyperphosphatemia: its consequences and 
treatment in patients with chronic renal disease. Am J Kidney Dis., Vol. 19, No. 4, 
pp. 303-317, ISSN 1523-6838 
D'Haese, P.C., Couttenye, M.M., Goodman, W.G., Lemoniatou, E., Digenis, P., Sotornik, I., 
Fagalde, A., Barsoum, R.S., Lamberts, L.V., De Broe, M.E. (1995). Use of the low-dose 
desferrioxamine test to diagnose and differentiate between patients with aluminium-
www.intechopen.com
 
Aluminum Overload: An Easily-Ignored Problem in Dialysis Patients with Hyperparathyroidism 
 
65 
related bone disease, increased risk for aluminium toxicity, or aluminium overload. 
Nephrol Dial Transplant., Vol. 10, No. 10, pp. 1874-1884, ISSN 1460-2385 
Díaz-Corte, C., Fernández-Martín, J.L., Barreto, S., Gómez, C., Fernández-Coto, T., Braga, S., 
Cannata, J.B. (2001). Effect of aluminium load on parathyroid hormone synthesis. 
Nephrol Dial Transplant., Vol. 16, pp. 742–745, ISSN 1460-2385 
Drüeke T. (1980). Dialysis osteomalacia and aluminum intoxication. Nephron Vol. 26, pp. 
207–210, ISSN 1660-2110 
Drüeke, T.B. (1990). Resistance to recombinant human erythropoietin in hemodialysis 
patients. Am J Nephrol., Vol. 10, Suppl. 2, pp. 34–39, ISSN 1421-9670 
Felsenfeld, A.J., Machado, L., Bover, J., Trinidad, P., Rodriguez, M. (1993). Effect of 
aluminium on the development of hyperparathyroidism and bone disease in the 
azotaemic rat. Nephrol Dial Transplant., Vol. 8, No. 4, pp. 325–334, ISSN 1460-2385 
Fernández-Martin, J.L., Canteros, A., Serrano, M., Gonzalez-Carcedo, A., Diaz-Corte, C., 
Cannata, J.B. (1998). Prevention of aluminium exposure through dialysis fluids. 
Analysis of changes in the last 8 years. Nephrol Dial Transplant., Vol. 13, Suppl 3, pp. 
78–81, ISSN 1460-2385 
Hewitt, C.D., Savory, J., Wills, M.R. (1990). Aspects of aluminum toxicity. Clin Lab Med., Vol. 
10, pp. 403–422, ISSN 1437-4331 
Hughes, J.R., and Schreeder, M.T. (1980). EEG in dialysis encephalopathy. Neurology., Vol. 
30, No. 11, pp. 1148-1154, ISSN 1526-632X 
Humpfner, A., Hummel, S., Schultz, W. (1993). Diagnosis and therapeutic approaches to 
aluminum overload in dialysed patients--representative study questionnaire in 
West German dialysis units in 1989-1990. Nephrol Dial Transplant., Vol. 8, Suppl. 1, 
pp. S51-S54, ISSN 1460-2385 
Jaffe, J.A., Liftman, C., Glickman, J.D. (2005). Frequency of elevated serum aluminum levels in 
adult dialysis patients. Am J Kidney Dis., Vol. 46, No. 2, pp. 316-319, ISSN 1523-6838 
Jeffery, E.H., Abreo, K., Burgess, E., Cannata, J., Greger, J.L. (1996). Systemic aluminum 
toxicity: effects on bone, hematopoietic tissue, and kidney. J Toxicol Environ Health., 
Vol. 48, pp. 649–665, ISSN 0098-4108 
Janssen, M.J., and van Boven, W.P. (1996). Efficacy of low-dose desferrioxamine for the 
estimation of aluminium overload in haemodialysis patients. Pharm World Sci., Vol. 
18, pp. 187-191, ISSN 1573-739X 
Jorge, C., Gil, C., Possante, M., Catarino, M.C., Cruz, A., Andrade, R., Teixeira, R., Santos, 
N., Ferreira, A. (1999). Use of a desferrioxamine "microdose" to chelate aluminum 
in hemodialysis patients. Clin Nephrol., Vol. 52, No. 5, pp. 335-336, ISSN 0301-0430 
Kan, W.C., Chien, C.C., Wu, C.C., Su, S.B., Hwang, J.C., Wang, H.Y. (2010). Comparison of 
low-dose deferoxamine versus standard-dose deferoxamine for treatment of 
aluminium overload among haemodialysis patients. Nephrol Dial Transplant., Vol. 
25, No. 5, pp. 1604-1608, ISSN 1460-2385 
Kausz, A.T., Antonsen, J.E., Hercz, G., Pei, Y., Weiss, N.S., Emerson, S., Sherrard, D.J. (1999). 
Screening plasma aluminum levels in relation to aluminum bone disease among 
asymptomatic dialysis patients. Am J Kidney Dis., Vol. 34, No. 4, pp. 688-693, ISSN 
1523-6838 
Koiwa, F., and Sato, Y. (2009). Chemistry and history of phosphate binder. Clin Calcium., 
Vol. 19, pp. 198-204, ISSN 0917-5857 
Losekann, A., Ureña, P., Khiraoui, F., Casadevall, N., Zins, B., Bererhi, L., Zingraff, J., 
Bourdon, R., Drüeke, T. (1990). Aluminium intoxication in the rat induces partial 
resistance to the effect of recombinant human erythropoietin. Nephrol Dial 
Transplant., Vol. 5, No. 4, pp. 258–263, ISSN 1460-2385 
www.intechopen.com
 
Hyperparathyroidism 
 
66
McCarthy, J.T., Milliner, D.S., Johnson, W.J. (1990). Clinical experience with desferrioxamine in 
dialysis patients with aluminium toxicity. Q J Med., Vol. 74, pp. 257-276, ISSN 1460-2393 
McCauley, J., and Sorkin, M.I. (1989). Exacerbation of aluminum encephalopathy after 
treatment with desferrioxamine. Nephrol Dial Transplant., Vol. 4, No. 2, pp. 110-114, 
ISSN 1460-2385 
Milliner, D.S., Nebeker, H.G., Ott, S.M., Andress, D.L., Sherrard, D.J., Alfrey, A.C., 
Slatopolsky, E.A., Coburn, J.W. (1984). Use of the deferoxamine infusion test in the 
diagnosis of aluminum-related osteodystrophy. Ann Intern Med., Vol. 101, No. 6, 
pp. 775-779, ISSN 1539-3704 
National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and 
disease in chronic kidney disease. (2003). Am J Kidney Dis., Vol. 42, pp. S108-S122, 
ISSN 1523-6838 
Norris, K.C., Crooks, P.W., Nebeker, H.G., Hercz, G., Milliner, D.S., Gerszi, K., Slatopolsky, E., 
Andress, D.L., Sherrard, D.J., Coburn J.W. (1985). Clinical and laboratory features of 
aluminum-related bone disease: Differences between sporadic and "epidemic" forms 
of the syndrome. Am J Kidney Dis., Vol. 6, pp. 342-347, ISSN 1523-6838 
Parkinson, I.S., Ward, M.K., Feest, T.G., Fawcett, R.W., Kerr, D.N. (1979). Fracturing dialysis 
osteodystrophy and dialysis encephalopathy. An epidemiological survey. Lancet, Vol. 
313, No. 8113, pp. 406–409, ISSN 1474-547X 
Pei, Y., Hercz, G., Greenwood, C., Sherrard, D., Segre, G., Manuel, A., Saiphoo, C., Fenton, S. 
(1992). Non-invasive prediction of aluminum bone disease in hemo- and peritoneal 
dialysis patients. Kidney Int., Vol. 41, No. 5, pp. 1374–1382, ISSN 1523-1755 
Pei, Y., Hercz, G., Greenwood, C., Segre, G., Manuel, A., Saiphoo, C., Fenton, S., Sherrard, D. 
(1993). Renal osteodystrophy in diabetic patients. Kidney Int., Vol. 44, No. 1, pp. 
159-164, ISSN 1523-1755 
Pengloan, J., Dantal, J., Rossazza, C., Abazza, M., Nivet, H. (1987). Ocular toxicity after a 
single intravenous dose of desferrioxamine in 2 hemodialyzed patients. Nephron, 
Vol. 46, No. 2, pp. 211-212, ISSN 1660-2110 
Petrikkos, G., and Drogari-Apiranthitou, M. (2011). Zygomycosis in immunocompromised 
non-haematological patients. Mediterr J Hematol Infect Dis., Vol. 3, No. 1, e2011012, 
ISSN 2035-3006 
Salusky, I.B. (2006). A new era in phosphate binder therapy: What are the options? Kidney 
Int., Vol. 105, pp. S10-S15, ISSN 1523-1755 
Savory, J., Berlin, A., Courtoux, C., Yeoman, B., Wills, M. (1989). Summary report of an 
international workshop on “The role of biological monitoring in the prevention of 
aluminum toxicity in man: Aluminum analysis in biological fluids.” Ann Clin Lab 
Sci., Vol. 13, pp. 444-451, ISSN 1550-8080 
Sherrard, D.J. (1974). Letter: the myth of aluminum toxicity. N Engl J Med., Vol. 290, pp. 750, 
ISSN 1533-4406 
Slatopolsky, E. (1987). The interaction of parathyroid hormone and aluminum in renal 
osteodystrophy. Kidney Int., Vol. 31, No. 3, pp. 842-854, ISSN 1523-1755 
Vincenti, F., Arnaud, S.B., Recker, R., Genant, H., Amend, W.J., Jr., Feduska, N.J., Salvatierra, 
O., Jr. (1984). Parathyroid and bone response of the diabetic patient to uremia. 
Kidney Int., Vol. 25, No. 4, pp. 677-682, ISSN 1523-1755 
Ward, M.K., Ellis, H.A., Feest, T.G., Parkinson, I.S., Kerr, D.N. (1978). Osteomalacic dialysis 
osteodystrophy: evidence for a water-borne aetiological agent, probably 
aluminium. Lancet, Vol. 311, No. 8069, pp. 841–845, ISSN 1474-547X 
www.intechopen.com
Hyperparathyroidism
Edited by Dr. Gonzalo Diaz Soto
ISBN 978-953-51-0478-0
Hard cover, 96 pages
Publisher InTech
Published online 04, April, 2012
Published in print edition April, 2012
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
This book is the result of the collaboration between worldwide authorities of different specialities in
hyperparathyroidism. It aims to provide a general but deep view of primary/secondary and tertiary
hyperparathyroidism, from a physiological basis to hyperparathyroidism in hemodialyzed patients, as well as
new treatment approaches, techniques and surgical scenarios. We hope that the medical and paramedical
researchers will find this book helpful and stimulating. We look forward to sharing knowledge of
hyperparathyroidism with a wider audience.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
Wei-Chih Kan, Chih-Chiang Chien, Yi-Hua Lu, Jyh-Chang Hwang, Shih-Bin Su and Hsien-Yi Wang (2012).
Aluminum Overload: An Easily-Ignored Problem in Dialysis Patients with Hyperparathyroidism,
Hyperparathyroidism, Dr. Gonzalo Diaz Soto (Ed.), ISBN: 978-953-51-0478-0, InTech, Available from:
http://www.intechopen.com/books/hyperparathyroidism/aluminum-overload-an-easily-ignored-problem-in-
dialysis-patients-with-hyperparathyroidism
© 2012 The Author(s). Licensee IntechOpen. This is an open access article
distributed under the terms of the Creative Commons Attribution 3.0
License, which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
